Yumanity Therapeutics Announces Positive Top-Line Results of Phase Ib Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase II

Yumanity Therapeutics, Inc. reported that its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled Phase Ib clinical trial in patients with mild-to-moderate Parkinson’s disease.